Goodwin is adept in patent prosecution across life sciences, biotech, pharmaceuticals, medical devices, software, hardware, data analytics, consumer electronics, business methods, financial systems, and e-commerce. Boston-based co-head Catherine McCarty specializes in pharmaceutical and chemistry-related IP, including small molecules, salts, solid forms, and chemical processes, and has handled related litigation. Silicon Valley-based co-chair James Riley advises emerging tech companies and venture capital firms on IP strategy, licensing, AI, data privacy, and technology-related financings and M&A. In Boston, Theresa Kavanaugh develops patent strategies for therapeutics, including NCEs, and biologics, guiding clients on FDA approvals, M&A, partnerships, and financings. Also in Boston are Scott Bluni and Duncan Greenhalgh. Other key contacts include Michael Shuster in San Francisco.
Legal 500 Editorial commentary
Accolades
Client satisfaction: Lawyer & team quality
Testimonials
Collated independently by Legal 500 research team.
- 'Michael Shuster brings decades of experience in IP litigation and protection - from the moment I started talking about what we were developing to where we want to take the technology, I felt that Michael was a partner working alongside me vs an external lawyer just putting in the time. That partnership is not only more pleasant to work with, but has fomented a great collaboration and partnership in driving my company's portfolio and product forward.'
Key clients
- Insulet Corporation
- Blueprint Medicines
- Vigil Neuroscience
- Kymera Therapeutics
- Sionna Therapeutics
- Anthos Therapeutics
- Calico Labs
- Immuno-Therapeutics Companies
- Ansa Biotechnologies
- Mission Bio, Inc.
- Ouro Medicines
- TRex Bio
Work highlights
Advised on the patent aspects of Blueprint Medicines Corporation’s (Nasdaq: BPMC) $9.5 billion acquisition by Sanofi (NASDAQ: SNY)
Advised Insulet Corporation in the case Insulet Corporation v. EOFlow Co. Ltd, achieving a landmark victory.
Advised on the patent aspects of Anthos Therapeutics’ acquisition by Novartis for up to $3.1 billion.
Practice head
Catherine McCarty; James Riley
Other key lawyers
Theresa Kavanaugh; Scott Bluni; Duncan Greenhalgh; Michael Shuster